Search research articles
Contact Us
Filters
Showing results (11-20 of 103) with videos related to
Page
of 11
Sort By:
Experimental Neurology
|
June 1, 1991
Ganglioside AGF2 prevents the cognitive impairments and cholinergic cell loss following intraventricular colchicine
D F Emerich, T J Walsh
Cell Transplantation
|
April 11, 2001
Update on immunoisolation cell therapy for CNS diseases
D F Emerich, H C Salzberg
Brain Research Bulletin
|
September 1, 1990
Neural basis of behavior: animal models of human conditions
P R Sanberg, D F Emerich
Physiology & Behavior
|
January 1, 1989
Selective working memory impairments following intradentate injection of colchicine: attenuation of the behavioral but not the neuropathological effects by gangliosides GM1 and AGF2
D F Emerich, T J Walsh
Brain Research Bulletin
|
May 20, 2003
Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport
C V Borlongan, D F Emerich
Biological Psychiatry
|
February 1, 1991
Neuroleptic dysphoria
D F Emerich, P R Sanberg
Pharmacology, Biochemistry, and Behavior
|
September 1, 1990
Hyperactivity following intradentate injection of colchicine: a role for dopamine systems in the nucleus accumbens
D F Emerich, T J Walsh
Cell Transplantation
|
May 20, 1998
Therapeutic potential of a polymer-encapsulated L-DOPA and dopamine-producing cell line in rodent and primate models of Parkinson's disease
M D Lindner, D F Emerich
Critical Reviews in Therapeutic Drug Carrier Systems
|
July 10, 2001
Immunoisolation cell therapy for CNS diseases
D F Emerich, S R Winn
Experimental Neurology
|
September 16, 1999
Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible?
J H Kordower, O Isacson, D F Emerich
Page
of 11
Search research articles
Search
Showing results (11-20 of 103) with videos related to
Sort By:
Page
of 11
Experimental Neurology
|
June 1, 1991
Ganglioside AGF2 prevents the cognitive impairments and cholinergic cell loss following intraventricular colchicine
D F Emerich, T J Walsh
Cell Transplantation
|
April 11, 2001
Update on immunoisolation cell therapy for CNS diseases
D F Emerich, H C Salzberg
Brain Research Bulletin
|
September 1, 1990
Neural basis of behavior: animal models of human conditions
P R Sanberg, D F Emerich
Physiology & Behavior
|
January 1, 1989
Selective working memory impairments following intradentate injection of colchicine: attenuation of the behavioral but not the neuropathological effects by gangliosides GM1 and AGF2
D F Emerich, T J Walsh
Brain Research Bulletin
|
May 20, 2003
Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport
C V Borlongan, D F Emerich
Biological Psychiatry
|
February 1, 1991
Neuroleptic dysphoria
D F Emerich, P R Sanberg
Pharmacology, Biochemistry, and Behavior
|
September 1, 1990
Hyperactivity following intradentate injection of colchicine: a role for dopamine systems in the nucleus accumbens
D F Emerich, T J Walsh
Cell Transplantation
|
May 20, 1998
Therapeutic potential of a polymer-encapsulated L-DOPA and dopamine-producing cell line in rodent and primate models of Parkinson's disease
M D Lindner, D F Emerich
Critical Reviews in Therapeutic Drug Carrier Systems
|
July 10, 2001
Immunoisolation cell therapy for CNS diseases
D F Emerich, S R Winn
Experimental Neurology
|
September 16, 1999
Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible?
J H Kordower, O Isacson, D F Emerich
Page
of 11